New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 10, 2013
17:03 EDTVRXValeant announces information regarding continuance proposal
Valeant Pharmaceuticals announced that it has provided additional information related to the proposal to continue Valeant into British Columbia under the British Columbia Business Corporations Act, or BCBCA. If the continuance is approved by shareholders, Valeant's current articles and by-laws will be replaced with a notice of articles and articles under the BCBCA. The new articles provide that shareholders seeking to nominate candidates for election as directors must provide timely written notice to Valeant. Valeant has modified the advance notice provision to provide that a shareholder's notice must be received by Valeant no later than the close of business on the 50th day before the meeting date.
News For VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
09:18 EDTVRXValeant and Progenics' Relistor eceives positive opinion from EMA
Valeant (VRX) and Progenics (PGNX) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for Relistor Subcutaneous Injection for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. Additionally, the Committee has recommended a one-year extension of data/marketing protection for Relistor, to 11 years from the date of approval.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use